tradingkey.logo


Sanofi SA

SNY

45.640USD

-3.610-7.33%
āļ›āļīāļ” 07/31, 16:00ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
114.43BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
16.85P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Sanofi SA āļšāļĢāļīāļĐāļąāļ—
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™SNY
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Sanofi SA
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJul 01, 2002
āļāđˆāļ­āļ•āļąāđ‰āļ‡āđ€āļĄāļ·āđˆāļ­1994
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Paul Hudson, Ph.D.
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™84587
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒDepository Receipt
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Jul 01
āļ—āļĩāđˆāļ­āļĒāļđāđˆ46 Avenue de la Grande Armee
āđ€āļĄāļ·āļ­āļ‡PARIS
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ Global Select Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻFrance
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ75017
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ33153774000
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.sanofi.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™SNY
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJul 01, 2002
āļāđˆāļ­āļ•āļąāđ‰āļ‡āđ€āļĄāļ·āđˆāļ­1994
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Ms. Clotilde Delbos
Ms. Clotilde Delbos
Independent Director
Independent Director
--
--
Mr. Frederic Oudea
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
--
--
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
4.90B
47.06%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
2.62B
25.20%
Europe
2.15B
20.65%
China
737.01M
7.08%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 24 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 24 āļ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Dodge & Cox
2.90%
Fisher Investments
0.54%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.44%
Capital World Investors
0.33%
Other
95.35%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Dodge & Cox
2.90%
Fisher Investments
0.54%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.44%
Capital World Investors
0.33%
Other
95.35%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor/Hedge Fund
5.32%
Investment Advisor
4.17%
Research Firm
0.71%
Hedge Fund
0.19%
Bank and Trust
0.07%
Family Office
0.02%
Pension Fund
0.02%
Other
89.51%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
1254
264.61M
10.47%
-15.39M
2025Q1
1286
268.29M
10.62%
-13.21M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
2023Q1
1174
268.83M
10.66%
-6.19M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Dodge & Cox
73.19M
2.9%
-2.03M
-2.70%
Mar 31, 2025
Fisher Investments
13.57M
0.54%
+1.06M
+8.43%
Mar 31, 2025
Invesco Advisers, Inc.
11.37M
0.45%
-3.25K
-0.03%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.03M
0.44%
+193.02K
+1.78%
Mar 31, 2025
Capital World Investors
8.32M
0.33%
+8.32M
--
Mar 31, 2025
Managed Account Advisors LLC
7.57M
0.3%
-172.21K
-2.22%
Mar 31, 2025
Barrow Hanley Global Investors
7.35M
0.29%
-347.84K
-4.52%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.68M
0.19%
-269.36K
-5.45%
Mar 31, 2025
Wellington Management Company, LLP
4.43M
0.18%
-56.88K
-1.27%
Mar 31, 2025
Boston Partners
4.09M
0.16%
-1.31M
-24.22%
Mar 31, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
VanEck Pharmaceutical ETF
4.48%
Simplify Health Care ETF
3.84%
Putnam Focused Large Cap Value ETF
2.55%
Brandes US Value ETF
2.08%
Invesco International Dividend Achievers ETF
2.05%
Pacer Global Cash Cows Dividend ETF
1.93%
Altrius Global Dividend ETF
1.8%
Invesco Nasdaq Biotechnology ETF
1.59%
ProShares Ultra Nasdaq Biotechnology
1.55%
T Rowe Price Equity Income ETF
1.19%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
VanEck Pharmaceutical ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™4.48%
Simplify Health Care ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.84%
Putnam Focused Large Cap Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.55%
Brandes US Value ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.08%
Invesco International Dividend Achievers ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™2.05%
Pacer Global Cash Cows Dividend ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.93%
Altrius Global Dividend ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.8%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.59%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.55%
T Rowe Price Equity Income ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.19%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 23.51B USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™